Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1998 September;42(3) > The Quarterly Journal of Nuclear Medicine 1998 September;42(3):166-78

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

ORIGINAL ARTICLES  NEU­RO­PHAR­MA­COL­O­GY


The Quarterly Journal of Nuclear Medicine 1998 September;42(3):166-78

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Neurochemical imag­ing of Alzheimer’s dis­ease and oth­er degen­er­a­tive demen­tias

Frey K. A., Minoshima S., Kuhl D. E.

From the Division of Nuclear Medicine Department of Internal Medicine University of Michigan, Ann Arbor, MI USA


FULL TEXT  


A ­wide varie­ty of neu­ro­chem­i­cal and func­tion­al imag­ing approach­es ­have ­been ­applied to the ­study of pro­gres­sive demen­tias, par­tic­u­lar­ly Alzheimer’s dis­ease (AD) and relat­ed dis­or­ders. Despite con­sid­er­able ­progress in the ­past ­decade, the ­cause(s) of ­most cas­es of AD ­remain unde­ter­mined and pre­ven­tive or pro­tec­tive ther­a­pies are lack­ing. Specifically-­designed imag­ing pro­ce­dures ­have per­mit­ted the test­ing of path­o­phy­sio­log­i­cal hypoth­e­ses of the eti­ol­o­gy and pro­gres­sion of AD, and ­have yield­ed impor­tant ­insights in sev­er­al are­as includ­ing the poten­tial ­roles of cere­bral cor­ti­cal chol­i­ner­gic ­lesions, cel­lu­lar inflam­ma­tion, and loss­es of cor­ti­cal syn­ap­ses. From the per­spec­tive of clin­i­cal diag­no­sis, PET glu­cose metab­olism imag­ing ­with use of [18F]2-flu­o­rod­e­ox­y­glu­cose (FDG) is the ­most sen­si­tive and spe­cif­ic imag­ing modal­ity yet iden­ti­fied. The over­all per­for­mance of PET FDG is favor­able for rou­tine clin­i­cal eval­u­a­tion of sus­pect­ed AD, and ­will like­ly ­gain increas­ing util­iza­tion in the ­near ­future. Assessments of glu­cose metab­olism and oth­er, spe­cif­ic ­aspects of neu­ro­chem­is­try in AD ­will pro­vide ­direct meas­ures of ther­a­peu­tic ­drug ­actions and may per­mit dis­tinc­tion of symp­to­mat­ic ver­sus dis­ease-mod­i­fy­ing ther­a­pies as ­they are devel­oped and intro­duced in clin­i­cal ­trials.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail